Central Trust Company’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$27.9K Sell
356
-92
-21% -$6.27K ﹤0.01% 1009
2026
Q1
$29K Buy
448
+94
+27% +$6.63K ﹤0.01% 945
2025
Q4
$23.8K Hold
354
﹤0.01% 941
2025
Q3
$26K Hold
354
﹤0.01% 928
2025
Q2
$18.4K Hold
354
﹤0.01% 1001
2025
Q1
$22.6K Hold
354
﹤0.01% 950
2024
Q4
$16.9K Hold
354
﹤0.01% 997
2024
Q3
$20.3K Hold
354
﹤0.01% 948
2024
Q2
$18.5K Hold
354
﹤0.01% 950
2024
Q1
$14.4K Hold
354
﹤0.01% 1019
2023
Q4
$13.1K Hold
354
﹤0.01% 1036
2023
Q3
$13.5K Buy
354
+54
+18% +$2.21K ﹤0.01% 995
2023
Q2
$10.8K Hold
300
﹤0.01% 1025
2023
Q1
$11.5K Hold
300
﹤0.01% 1029
2022
Q4
$17.1K Hold
300
﹤0.01% 940
2022
Q3
$12K Sell
300
-23
-7% -$1.02K ﹤0.01% 1008
2022
Q2
$14K Hold
323
﹤0.01% 992
2022
Q1
$13K Buy
323
+23
+8% +$819 ﹤0.01% 1037
2021
Q4
$12K Hold
300
﹤0.01% 1034
2021
Q3
$12K Hold
300
﹤0.01% 1006
2021
Q2
$14K Buy
+300
New +$13.3K ﹤0.01% 954

Other funds holding HALO

Central Trust Company's HALO Position: Q2 2026 in Review

Central Trust Company reduced its Halozyme (HALO) stake by 21% in Q2 2026, selling an estimated $6.27K and leaving 356 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1009.

Central Trust Company first reported a position in HALO in Q2 2021 and has held it in 21 quarters since. The position peaked at $29K in Q1 2026. 236 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Central Trust Company held 356 shares of Halozyme worth $27.9K as of Q2 2026.
  • Central Trust Company sold 92 Halozyme shares in Q2 2026, an estimated $6.27K.
  • Halozyme made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1009 holding.
  • Central Trust Company first reported a position in Halozyme in Q2 2021 and has held it in 21 quarters since.
  • Central Trust Company's Halozyme position peaked at $29K in Q1 2026.
  • 236 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.